Polypeptide and immune modulation

A pharmaceutical composition that comprises:

• an isolated, recombinant Roseburia flagellin polypeptide in a unit dose comprising a therapeutically effective amount sufficient to reduce inflammation by increasing a level of IL-10 when the unit dose is administered to a subject suffering from a gastrointestinal inflammatory disorder or an autoimmune disorder, relative to an extent inflammation prior to the administering, wherein the isolated, recombinant Roseburia flagellin polypeptide comprises:
• a polypeptide sequence having at least 85% identity to the polypeptide sequence of SEQ ID NO:
• 2, as determined by a sequence alignment performed using BLAST, wherein said polypeptide sequence comprises a region that has at least 90% identity to the polypeptide sequence of amino acids 79-117 of SEQ ID NO:
• 2, as determined by a sequence alignment performed using BLAST;
• and
• a preservative or stabilizer, and
• wherein the isolated, recombinant Roseburia flagellin polypeptide binds to TLR5.